{"title":"Phase II study of isotretinoin in the treatment of advanced non-small cell lung cancer.","authors":"S M Grunberg, L M Itri","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1097-8"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13962081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M Prados, L Rodriguez, M Seager, P Silver, V Levin
{"title":"Phase II study of spirohydantoin mustard for the treatment of recurrent malignant gliomas.","authors":"M Prados, L Rodriguez, M Seager, P Silver, V Levin","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1105-6"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14249809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I Quirt, E Eisenhauer, V Bramwell, M Knowling, C Grafton, W Hirte, M Cripps, A Maksymiuk
{"title":"Phase II study of mitoxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas.","authors":"I Quirt, E Eisenhauer, V Bramwell, M Knowling, C Grafton, W Hirte, M Cripps, A Maksymiuk","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1109-10"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14251189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J L Grem, D D Shoemaker, N J Petrelli, H O Douglass
{"title":"Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma.","authors":"J L Grem, D D Shoemaker, N J Petrelli, H O Douglass","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1122"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14623427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P Presgrave, R L Woods, M H Tattersall, A S Coates, J A Levi, R M Fox, D Hedley
Thirty-six adult patients with measurable advanced soft tissue sarcoma were treated with a combination of doxorubicin (70 mg/m2) and methotrexate (50 mg/m2) iv every 21 days. Partial remission was seen in ten of 33 evaluable patients (30%). Median duration of remission was 23 weeks, and median survival was 42 weeks. Bone marrow toxicity was the main toxic effect; 23% of the patients had a nadir leukocyte count less than 2.0 X 10(9)/L during therapy. These results do not suggest any therapeutic advantage in adding methotrexate to doxorubicin in this context.
{"title":"Chemotherapy of adult soft tissue sarcoma with combination of doxorubicin and methotrexate.","authors":"P Presgrave, R L Woods, M H Tattersall, A S Coates, J A Levi, R M Fox, D Hedley","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Thirty-six adult patients with measurable advanced soft tissue sarcoma were treated with a combination of doxorubicin (70 mg/m2) and methotrexate (50 mg/m2) iv every 21 days. Partial remission was seen in ten of 33 evaluable patients (30%). Median duration of remission was 23 weeks, and median survival was 42 weeks. Bone marrow toxicity was the main toxic effect; 23% of the patients had a nadir leukocyte count less than 2.0 X 10(9)/L during therapy. These results do not suggest any therapeutic advantage in adding methotrexate to doxorubicin in this context.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1087-8"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14796899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thirty-two cases of esophageal cancer were treated with thermochemotherapy from August 1984 to June 1985. A combination of bleomycin (20 mg per session iv) and cisplatin (0.5-0.9 mg/kg per session as low dose and 1.0-2.0 mg/kg per session as high dose), or of bleomycin, cisplatin (high dose), and cyclophosphamide (400-600 mg per session) were the treatment regimens. A 915-MHz microwave applicator was inserted into the lumen of the esophagus for heating. The temperature at normal adjacent tissue to the cancer was at 43-44 degrees C, while the temperature of the cancer was at 45 degrees C-50 degrees C. Chemotherapy and hyperthermia were administered simultaneously, once a week for six to eight sessions. The response rate in the low-dose group was 36.4% (four of 11) and 81% (17 of 21) in the high-dose group. The complete response rate in the low-dose group was zero of 11 patients, with 38.1% (eight of 21) in the latter group. The relationship between power output and tumor response is also discussed.
{"title":"Preliminary report on the treatment of esophageal cancer by intraluminal microwave hyperthermia and chemotherapy.","authors":"D J Li, B S Hou","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Thirty-two cases of esophageal cancer were treated with thermochemotherapy from August 1984 to June 1985. A combination of bleomycin (20 mg per session iv) and cisplatin (0.5-0.9 mg/kg per session as low dose and 1.0-2.0 mg/kg per session as high dose), or of bleomycin, cisplatin (high dose), and cyclophosphamide (400-600 mg per session) were the treatment regimens. A 915-MHz microwave applicator was inserted into the lumen of the esophagus for heating. The temperature at normal adjacent tissue to the cancer was at 43-44 degrees C, while the temperature of the cancer was at 45 degrees C-50 degrees C. Chemotherapy and hyperthermia were administered simultaneously, once a week for six to eight sessions. The response rate in the low-dose group was 36.4% (four of 11) and 81% (17 of 21) in the high-dose group. The complete response rate in the low-dose group was zero of 11 patients, with 38.1% (eight of 21) in the latter group. The relationship between power output and tumor response is also discussed.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1013-9"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13592689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ifosfamide plus 5-fluorouracil for treatment of adenocarcinoma of the pancreas.","authors":"P J Loehrer, S D Williams, C R Nichols","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1115-6"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14251191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G Fraschini, G Fleishman, C Charnsangavej, C H Carrasco, G N Hortobagyi
We assessed the therapeutic efficacy and toxicity of continuous hepatic infusion of vinblastine in the treatment of breast cancer predominantly metastatic to the liver. Twenty-six patients previously treated with one or more chemotherapeutic regimens received vinblastine at a dose of 2.0 mg/m2 daily for 5 days, via percutaneously inserted intra-arterial catheters, at 3-4-week intervals. Nine of 25 evaluable patients (36%) achieved partial response and four (16%) had minor response. For responding patients, the median time to disease progression was 21 weeks (range, 12-99), with a median survival of 11 months (range, 4-29) from the beginning of hepatic arterial infusion. The toxicity of the treatment was acceptable, and drug-related effects were comparable to those seen in patients with breast cancer treated by iv continuous infusion of vinblastine at slightly lower doses. We observed two episodes of transient inappropriate antidiuretic hormone secretion. Percutaneous hepatic arterial infusion of vinblastine had significant activity in the treatment of breast cancer metastatic to the liver.
{"title":"Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy for metastatic breast cancer.","authors":"G Fraschini, G Fleishman, C Charnsangavej, C H Carrasco, G N Hortobagyi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We assessed the therapeutic efficacy and toxicity of continuous hepatic infusion of vinblastine in the treatment of breast cancer predominantly metastatic to the liver. Twenty-six patients previously treated with one or more chemotherapeutic regimens received vinblastine at a dose of 2.0 mg/m2 daily for 5 days, via percutaneously inserted intra-arterial catheters, at 3-4-week intervals. Nine of 25 evaluable patients (36%) achieved partial response and four (16%) had minor response. For responding patients, the median time to disease progression was 21 weeks (range, 12-99), with a median survival of 11 months (range, 4-29) from the beginning of hepatic arterial infusion. The toxicity of the treatment was acceptable, and drug-related effects were comparable to those seen in patients with breast cancer treated by iv continuous infusion of vinblastine at slightly lower doses. We observed two episodes of transient inappropriate antidiuretic hormone secretion. Percutaneous hepatic arterial infusion of vinblastine had significant activity in the treatment of breast cancer metastatic to the liver.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 11","pages":"1001-5"},"PeriodicalIF":0.0,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14796895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号